Please assess the completion status of the following clinical trial:

Trial Title: Indomethacin Decreases Post-ERCP Pancreatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* If they met one or more of the following criteria:~  * a clinical suspicion of SOD dysfunction;~ * or a history of post-ERCP pancreatitis, pancreatic~ * or precut sphincterotomy,~ * more than eight cannulation attempts,~ * pneumatic dilatation of an intact biliary sphincter,~ * or ampullectomy~* Patients were also eligible for inclusion if they met two of the following criteria:~  * aged 50 years or younger and female gender~ * or a history of recurrent pancreatitis (\>2 episodes),~ * three or more injections of contrast agent into the pancreatic duct with at least one injection to the tail of the pancreas,~ * excessive injection of contrast agent into the pancreatic duct resulting in opacification of pancreatic acini,~ * or the need for acquisition of a cytology specimen from the pancreatic duct with the use of a tissue-sampling brush.~Exclusion Criteria:~* unwillingness or inability to consent for the study~* pregnancy~* breast feeding~* standard contraindications for ERCP~* hypersensitivity to aspirin or NSAIDs~* previous use of NSAIDs within 1 week~* renal failure (creatinine clearance rate \>1.4 mg/dL)~* active or recent (\< 4 weeks) gastrointestinal hemorrhage~* chronic calcified pancreatitis~* pancreatic head malignancy~* any procedure performed on the major papilla/ventral pancreatic duct in patients with a pancreatic divisum~* previous ERCP for biliary stent removal or exchange without an anticipated pancreatogram~* subjects with prior biliary sphincterotomy and scheduled for repeat biliary therapy without an anticipated pancreatogram~* or anticipated inability to follow our protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Indomethacin (Type: EXPERIMENTAL): 100 mg of Indomethacin suppository immediately afterwards while still under sedation
- 2.6-g suppository of glycerin (Type: PLACEBO_COMPARATOR): suppository of 2.4 g of glycerin immediately afterwards while still under sedation

Based on this trial design, predict the completion outcome and termination type (if applicable).